Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a ...
The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...
22h
Hosted on MSNBiodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence PeaksShares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...
2h
MT Newswires on MSNEuropean Equities Traded in the US as American Depositary Receipts Rise in Tuesday TradingEuropean equities traded in the US as American depositary receipts were higher late Tuesday morning, rising 0.59% to 1,393.03 on the S&P Europe Select ADR Index. From continental Europe, the gainers ...
DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...
After hours: February 7 at 6:37:07 PM EST Loading Chart for BDRX ...
Biodexa Pharmaceuticals reports updates from the MAGIC-1 study on MTX110 for recurrent glioblastoma. MTX110 has also demonstrated potential in treating diffuse midline glioma, a rare brain cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results